Document is current

Article History

Received: 16 July 2021

Accepted: 21 January 2022

First Online: 3 March 2022

Competing interests

: There are no conflicts of interests concerning the research related to the manuscript to be reported. A.A.-C. has received speaker honoraria from AbbVie, Zambon, Krka, and Lundbeck. She has participated in advisory boards for Zambon. She has received scientific research funding from Italfarmaco. B.R.B. serves as the co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for Biogen and UCB (paid to the Institute, not to B.R.B.), has received fees for speaking at conferences from AbbVie, Biogen, UCB, Zambon, Roche, GE Healthcare and Bial (paid to the Institute, not to B.R.B.), and has received research support from the Netherlands Organization for Health Research and Development, the Michael J Fox Foundation, UCB, AbbVie, the Stichting Parkinson Fonds, Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health and the Parkinson Vereniging, outside the submitted work. B.R.B. does not hold any stocks or stock options with any companies that are connected to Parkinson’s disease or to any of the topics in this paper.